

- 2 **Viskosuplementace v léčbě osteoartrózy**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 2 **Prognostické faktory pro setrvání na abataceptu po předchozí biologické léčbě – studie ACTION**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 2 **Účinnost abataceptu v léčbě revmatoidní artritidy v každodenní praxi – studie ACTION**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha | prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 3 **Doporučení pro terapii antirevmatiky v graviditě a laktaci**
MUDr. Dana Tegzová Revmatologický ústav, Praha
- 3 **Jak postupovat u pacientů s psoriatickou artritidou po selhání anti-TNF**
MUDr. Jiří Štolfa Revmatologický ústav, Praha
- 4 **Nové poznatky při dávkování metotrexátu v léčbě revmatoidní artritidy**
MUDr. Radka Moravcová Revmatologický ústav, Praha
- 5 **Biosimilars – co je nového?**
MUDr. Šárka Forejtová Revmatologický ústav, Praha
- 6 **Hodnocení magnetické rezonance u non-radiografické axiální spondyloartritidy**
MUDr. Kristýna Grobelná | MUDr. Michal Tomčík, Ph.D. | prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 6 **Suplementace kalcie a vitamínem D při zahájení léčby glukokortikoidy**
MUDr. Olga Růžičková Revmatologický ústav, Praha
- 7 **Lokální terapie ketoprofenem**
MUDr. Kateřina Zegzulková Revmatologický ústav, Praha
- 7 **Pravděpodobnost setrvání na biologické léčbě u nemocných s revmatoidní artritidou – metaanalýza**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 7 **Ukončení biologické léčby u osob s revmatoidní artritidou**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 8 **Mukopolysacharidóza I v revmatologické ambulanci**
MUDr. RNDr. Pavel Ješina, Ph.D. Ústav dědičných metabolických poruch 1. LF UK a VFN, Praha
- 8 **Metotrexát v kombinační léčbě revmatoidní artritidy**
MUDr. David Suchý, Ph.D. Oddělení klinické farmakologie FN, Plzeň
- 9 **Prolia – dlouhodobě účinná a bezpečná léčba postmenopauzální osteoporózy**
prof. MUDr. Pavel Horák, CSc. III. interní klinika – nefrologická, revmatologická, endokrinologická, FN a LF UP, Olomouc

Viskosuplementace v léčbě osteoartrózy

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- Helmick, C. G. – Nelson, D. T. – Lawrence, R. C., et al.: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. *Arthritis Rheum*, 2008, 58, s. 15–25.
- Lawrence, R. C. – Helmick, C. G. – Arnett, F. C., et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. *Arthritis Rheum*, 1998, 41, s. 778–799.
- Pavelka, K. – Olejárová, M.: Osteoartróza. In: Pavelka, K. – Vencovský, J. – Horák, P., et al.: *Revmatologie*. Maxdorf, Praha, 2012, s. 448–463.
- Balazs, E. A.: Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. *Surg Technol Int*, 2004, 12, s. 278–289.
- Altman, R. D. – Manjoo, A. – Fierlinger, A., et al.: The mechanism of action for hyaluronic acid treatment in the osteoarthritis knee: a systematic review. *BMC Musc Dis*, 2015, 16, s. 321.
- Brun, P. – Zavan, B. – Vindigni, V., et al.: In vitro response of osteoarthritic chondrocytes and fibroblast-like synoviocytes to a 500–730 kDa hyaluronan amide derivative. *J Biomed Mater Res B Appl Biomater*, 2012, 100, s. 2073–2081.
- Karna, E. – Mityk, W. – Surazynski, A. – Palka, J. A.: Protective effect of hyaluronic acid on interleukin-1-induced deregulation of beta1-integrin and insulin-like growth factor-1 receptor signaling and collagen biosynthesis in cultured human chondrocytes. *Mol Cell Biochem*, 2008, 308, s. 57–64.
- Li, J. – Gorski, D. J. – Anemaet, W., et al.: Hyaluronan injection in murine osteoarthritis prevents TGFbeta 1-induced synovial neovascularization and fibrosis and maintains articular cartilage integrity by a CD44-dependent mechanism. *Arthritis Res Ther*, 2012, 14, s. R151.
- Ghosh, P. – Guidolin, D.: Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects of molecular weight dependent? *Semin Arthritis Rheum*, 2002, 32, s. 10–37.
- Bellamy, N. – Cambell, J. – Robinson, V.: Viscosupplementation for the osteoarthritis of the knee. *Cochrane Database Syst Rev*, 19. 4. 2006, CD005321.
- Richette, P. – Chevalier, X. – Ea, H. K., et al.: Hyaluronan for knee osteoarthritis: an updated meta-analysis of trial with low risk of bias. *RMD Open*, 2015, 1, s. e000071, doi:10.1136/mdopen.2015-000071.
- Jordan, K. M. – Arden, N. K. – Doherty, M., et al.: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESICIT). *Ann Rheum Dis*, 2003, 62, s. 1145–1155.
- Zhang, W. – Moskowitz, R. W. – Nuki, G., et al.: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage*, 2008, 16, s. 137–162.
- McAlindon, T. E. – Bannuru, R. R. – Sullivan, M. C., et al.: OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage*, 2014, 22, s. 363–388.
- Hochberg, M. C. – Altman, R. D. – April, K. T., et al.: American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)*, 2012, 64, s. 465–474.
- Henrotin, M. D. – Raman, R. – Richette, P.: Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. *Semin Arthritis Rheum*, 2015, 45, s. 140–149.
- Navarro-Sarabia, F. – Coronel, P. – Collantes, E., et al.: A 40-month, multicentre, randomised placebo-controlled study of assess the efficacy and carry over effect of repeated intraarticular injections of hyaluronic acid in knee osteoarthritis? The AMELIA project. *Ann Rheum Dis*, 2011, 70, s. 1957–1962.
- Bannuru, R. R. – Schmid, C. H. – Kent, D. M.: Comparative effectiveness of pharmacologic interventions for the knee osteoarthritis. A systematic review and network meta-analysis. *An Intern Med*, 2015, 162, s. 46–54.
- Jubb, R. W. – Piva, S. – Beinat, L., et al.: A one-year, randomised, placebo (saline) controlled clinical trial of 500–730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. *Int J Clin Pract*, 2003, 57, s. 467–474.
- Wang, Y. – Hall, S. – Hanna, F., et al.: Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. *BMC Musculoskeletal Disord*, 2011, 12, s. 195.
- Altman, R. – Lim, S. – Steen, R. G., et al.: Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: evidence from a large U.S. health claims database. *Plos One*, DOI:10.1371/journal.pone.0145776, 22. 12. 2015.
- Mc Alindon, M. – Nannuru, R. R.: Osteoarthritis: is viscosupplementation really so unsafe for knee OA? *Nat Rev Rheumatol*, 2012, 8, s. 635–636.
- Arrich, J. – Piribauer, F. – Mad, P., et al.: Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. *CMAJ*, 2005, 172, s. 1039–1043.
- Cabezas, R. – de la Serna, R. – Riviere, M.: Local treatment of rhizartritis (Suplasyn) versus dexamethasone. A prospective, randomized study. *Ann Rheum Dis*, 2003, 62, dopl., s. 267.
- Lieberman, J. R. – Engström, S. – Solovyov, O., et al.: Is intraarticular hyaluronic acid effective in treating osteoarthritis of the hip joint? *J Arthroplasty*, 2015, 30, s. 507–511.
- Bruyère, O. – Cooper, C. – Pelletier, J. P., et al.: An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Semin Arthritis Rheum*, 2014, 44, s. 253–263.

Prognostické faktory pro setrvání na abataceptu po předchozí biologické léčbě – studie ACTION

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- Nusslein, H. G. – Alten, R. – Galeazzi, M., et al.: Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. *BMC Musculoskeletal Disord*, 2015, 16, s. 176.
- Gottenberg, J. E. – Ravaud, P. – Cantagrel, A., et al.: Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. *Ann Rheum Dis*, 2012, 71, s. 1815–1819.
- Scarsi, M. – Ziglioli, T. – Airò P.: Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. *J Rheumatol*, 2011, 38, s. 2105–2111.
- Saevardottir, S. – Staviarz, L. – Turesson, C. – Linblad, S.: Previous biological therapies influence drug survival in rheumatoid arthritis patients starting abatacept treatment 2006–2012. *Ann Rheum Dis*, 2015, 72, s. 626.
- Finckh, A. – Iannone, F. – Reino, J. G. – Neto, D. – Lie, E. – van Riel, P.: The impact of inadequate response to prior biologic agents on abatacept drug retention in rheumatoid arthritis patients. A pan-European analysis of RA registries. *Arthritis Rheum*, 2013, 65, s. S217.

Účinnost abataceptu v léčbě revmatoidní artritidy v každodenní praxi – studie ACTION

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- Du Pan, S. M. – Dealer, S. – Ciurea, A., et al.: Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. *Arthritis Rheum*, 2009, 61, s. 560–568.
- Hyrich, K. L. – Lunt, M. – Watson, K. D., et al.: Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. *Arthritis Rheum*, 2007, 56, s. 13–20.
- Du Pan, S. M. – Scherer, A. – Gabay, C. – Finckh, A.: Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. *Ann Rheum Dis*, 2012, 71, s. 997–999.
- Kievit, W. – Franssen, J. – Oerlemans, A. J., et al.: The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomized controlled trials and clinical practice. *Ann Rheum Dis*, 2007, 66, s. 1473–1478.
- Nusslein, H. G. – Alten, R. – Galeazzi, M., et al.: Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. *BMC Musculoskeletal Disord*, 2014, 15, s. 14.

Komentář k článku: Účinnost abataceptu v léčbě revmatoidní artritidy v každodenní praxi

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Nüsslein, H. G. – Alten, R. – Galeazzi, M., et al.: Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. *BMC Musculoskeletal Disorders*, 2014, 15, s. 14. doi: 10.1186/1471-2474-15-14.
- 2 Nüsslein, H. G. – Alten, R. – Galeazzi, M., et al.: Prognostic factors for abatacept retention in patients who received at least one prior biological agent: an interim analysis from the observational, prospective ACTION study. *BMC Musculoskeletal Disorders*, 2015, 16, s. 176. doi: 10.1186/s12891-015-0636-9.
- 3 Smolen, J. S. – Landewé, R. – Breedveld, F. C., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. *Ann Rheum Dis*, 2010, 69, s. 964–975.
- 4 Strehl, C. – Bijlsma, J. W. – de Wit, M., et al.: Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. *Ann Rheum Dis*, 2016, 75, s. 952–957.
- 5 Chatzidionysiou, K. – Lie, E. – Nasonov, E., et al.: Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. *Ann Rheum Dis*, 2011, 70, s. 1575–1580.

Doporučení pro terapii antirevmatiky v graviditě a laktaci

MUDr. Dana Tegzová Revmatologický ústav, Praha

- 1 Götestam Skorpén, C. – Hoeltzenbein, M. – Tincani, A., et al.: The EULAR point to consider for use of antirheumatic drugs before pregnancy and during pregnancy and lactation. *Ann Rheum Dis*, 2016, 0, s. 1–16.
- 2 Koh, J. H. – Ko, H. S. – Ju, J. H., et al.: Hydroxychloroquine and pregnancy in Korean patients with SLE. *Lupus*, 2015, 24, s. 210–217.
- 3 Weber-Schoendorfer, C. – Chambers, C. – Wacker, E., et al.: Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. *Reprod Toxicol*, 2014, 66, s. 1101–1110.
- 4 Ostensen, M. – Khamasta, M. – Lockshin, et al.: Anti-inflammatory and immunosuppressive drugs and reproduction. *Arthritis Res Ther*, 2006, 8, s. 209.
- 5 Clowse, M. E. – Magder, L. – Winter, F., et al.: Hydroxychloroquine in lupus pregnancy. *Arthritis Rheum*, 2006, 54, s. 3640–3647.
- 6 Langagegaard, V. – Pedersen, L. – Gislum, M., et al.: Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. *Aliment Pharmacol Ther*, 2007, 25, s. 73–81.
- 7 Silva, C. A. – Hilario, M. O. – Febronio, M. V., et al.: Pregnancy outcome in juvenile SLE: a Brazilian multicenter cohort study. *J Rheumatol*, 2008, 35, s. 1414–1418.
- 8 Janssen, N. M. – Genta, M. S.: The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy and lactation. *Arch Intern Med*, 2000, 160, s. 610–619.
- 9 Nelson, J. L. – Ostensen, M.: Pregnancy and rheumatoid arthritis. *Rheum Dis Clin North Am*, 1997, 23, s. 195–212.
- 10 Dostál, C. – Vencovský, J.: Těhotenství a SLE. In: *Systémový lupus erythematosus*. Medprint, 1997, s. 147–153.
- 11 Briggs, G. G. – Freeman, R. K. – Yaffe, S. J.: *Drugs in pregnancy and lactation*. Baltimore, Williams and Wilkins, 1998.
- 12 Nelson, J. L. – Ostensen, M.: Pregnancy and rheumatoid arthritis. *Rheum Dis Clin North Am*, 1997, 23, s. 195–212.
- 13 Ostensen, M. – Ostensen, H.: Safety of nonsteroidal anti-inflammatory drugs in pregnant patients with rheumatic diseases. *J Rheumatol*, 1996, 23, s. 1045–1049.
- 14 Norgard, B. – Pedersen, L. – Christensen, L. A., et al.: Therapeutic drug use in women with Crohns disease and birth outcomes: a Danish nationwide cohort study. *Am J Gastroenterol*, 2007, 102, s. 1406–1413.
- 15 Blanford, A. T. – Murphy, B. P.: In vitro metabolism of prednisolone, dexamethasone, betamethasone and cortisol by the human placenta. *Am J Obstet Gynecol*, 1977, 27, s. 264–268.
- 16 Caritis, S. – Sibai, B. – Hauth, J., et al.: Low aspirin to prevent pre-eclampsia in women at high risk. *N Engl J Med*, 1998, 338, s. 701–705.
- 17 Hunt, B. J. – Doughty, H. – Majumdar, G., et al.: Thromboprophylaxis with low molecular weight heparin in high-risk pregnancy. *Thrombo Haemost*, 1997, 77, s. 39–43.
- 18 Parke, A. – West, B.: Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. *J Rheumatol*, 1996, 23, s. 1715–1718.
- 19 American college of rheumatology subcommittee on rheumatoid arthritis guidelines: Guidelines for the management of rheumatoid arthritis. 2002 update. *Arthritis Rheum*, 2002, 46, s. 328–346.
- 20 Ghogomu, E. A. – Maxwell, L. J. – Buchbinder, R., et al.: Updated method guidelines for cochrane musculoskeletal group systematic reviews and metaanalyses. *J Rheumatol*, 2014, 41, s. 194–205.
- 21 Hviid, A. – Mølgaard-Nielsen, D.: Corticosteroid use during pregnancy and risk of orofacial clefts. *CMAJ*, 2011, 183, s. 796–804.
- 22 Izmirly, P. M. – Costedoat-Chalumeau, N. – Piscovi, C. N., et al.: Maternal use of hydroxychloroquine is associated with reduced risk of recurrent anti-SSA/Ro- antibody-associated cardiac manifestation of neonatal lupus. *Circulation*, 2012, 126, s. 76–82.
- 23 Burns, P. B. – Rohrich, R. J., et al.: The levels of evidence and their role in evidence-based medicine. *Plast Reconstr Surg*, 2011, 128, s. 305–310.
- 24 Van Gelder, M. M. – Roeleveld, N. – Nordeng, H.: Exposure to non-steroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: a prospective cohort study. *PLoS ONE*, 2011, 6, s. e22174.
- 25 Daniel, S. – Matok, I. – Gorodischer, R., et al.: Major malformations following exposure to nonsteroidal anti-inflammatory drugs during the first trimester of pregnancy. *J Rheumatol*, 2012, 39, s. 2163–2169.

Jak postupovat u pacientů s psoriatickou artritidou po selhání anti-TNF

MUDr. Jiří Štolfa Revmatologický ústav, Praha

- 1 Gossec, L. – Smolen, J. S. – Gaujoux-Viala, C., et al.: European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. *Ann Rheum Dis*, 2012, 71, s. 4–12.
- 2 Nielsen, O. H. – Bukhave, K. – Elmgreen, J., et al.: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. *Dig Dis Sci*, 1987, 32, s. 577–582.
- 3 Nash, P. – Thaci, D. – Behrens, F., et al.: Lefunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. *Dermatology*, 2006, 212, s. 238–249.
- 4 Mease, P. J. – Armstrong, A. W.: Managing patients with psoriatic arthritis: The diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. *Drugs*, 2014, 74, s. 423–441.
- 5 Kristensen, E. L. – Golfe, A. – Saxne, T., et al.: Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. *Ann Rheum Dis*, 2008, 67, s. 364–369.
- 6 Hsu, L. – Snoggrass, B. T. – Armstrong, A. W.: Antidrug antibodies in psoriasis: a systematic review. *Br J Dermatol*, 2014, 170, s. 261–273.
- 7 Bito, T. Z. – Nishikawa, R. – Hatakeyama, M., et al.: Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. *Br J Dermatol*, 2014, 170, s. 922–629.
- 8 Mok, C. C. – van der Kleij, D. – Wolbink, G. J.: Drug levels, anti-drug antibodies, and clinical efficacy of anti-TNFalpha biologics in rheumatic diseases. *Clin Rheumatol*, 2013, 32, s. 1429–1435.
- 9 Zisapel, M. – Zisman, D. – Madar-Balakirski, N., et al.: Prevalence of TNF-alpha blocker immunogenicity in psoriatic arthritis. *J Rheumatol*, 2015, 42, s. 73–78.
- 10 Lie, E. – van der Heijde, D., et al.: The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. *Ann Rheum Dis*, 2014, 73, s. 132–137.
- 11 Karanikolas, G. N. – Katsalira, A. Q., et al.: Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month non randomized unblinded clinical trial. *J Rheumatol*, 2011, 38, s. 2466–2474.
- 12 Gossec, L. – Smolen, J. S. – Ramiro, S., et al.: European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis*, 2015, 0, s. 1–12.
- 13 Fagerli, K. M. – Lie, E. – van der Heijde, D., et al.: Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. *Ann Rheum Dis*, 2013, 72, s. 1840–1844.
- 14 Glinthborg, G. – Ostergard, M. – Krogh, N. S., et al.: Clinical response, drug survival and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: Results from the Danish Nationwide DANBIO Registry. *Arthritis Rheum*, 2013, 65, s. 1213–1223.
- 15 Mease, P. J. – Fleischmann, R. M. – Wollenhaupt, J., et al.: Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure. *Rheumatology*, 2014, 53, s. i137–i138.
- 16 Ritchlin, C. T. – Gottlieb, A. B. – McInnes, I. B., et al.: Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: results of a phase 3, multicenter, double-blind, placebo-controlled study (abstrakt 2557). *Arthritis Rheum*, 2012, 64, s. S1080–S1081.
- 17 Ritchlin, C. – Rahman, P. – Kavanaugh, A., et al.: PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumor necrosis factor therapy: 6-month and 1-year results of the phase 3, multicenter, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. *Ann Rheum Dis*, 2014, 73, s. 990–999.
- 18 Noordenbos, T. – Yeremenko, N. – Gofita, I., et al.: Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. *Arthritis Rheum*, 2012, 64, s. 99–109.
- 19 Kavanaugh, A. – McInnes, I. B. – Mease, P. J., et al.: Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis in anti-TNF-naïve patients and those previously exposed to anti-TNF therapy: 52-week results from a randomized, double-blind, placebo-controlled phase 3 trial with subcutaneous dosing. 2015, výroční zasedání ACR/ARHP, poprvé publikováno: 29. 9. 2015.
- 20 Fleischman, R. – Kremer, J. – Cush, J., et al.: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med*, 2012, 367, s. 495–507.
- 21 Ghoresli, K. – Laurince, A. – O'Shia, J. J.: Janus kinases in immune

- cell signaling. *Immunol Rev*, 2009, 228, s. 273–287.
- 22 Papp, K. A. – Menter, A. – Strober, B., et al.: Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose ranging study. *Br J Dermatol*, 2012, 167, s. 668–677.
 - 23 Schafer, P. H. – Parton, A. – Sandhi, A. K., et al.: Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. *Br J Pharmacol*, 2010, 159, s. 842–855.
 - 24 Schett, G. – Wollenhaupt, J. – Papp, K., et al.: Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum*, 2012, 64, s. 3156–3167.
 - 25 Kavanaugh, A. – Mease, P. J. – Gomez-Reino, J. J., et al.: Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial (abstrakt L13). *Arthritis Rheum*, 2012, 64, s. 4172–4173.
 - 26 Celgene International Sarl. Apremilast achieves statistical significance for the primary endpoint of the first phase III study (PALACE-1) in patients with psoriatic arthritis. Tisková zpráva, 2012.
 - 27 Mease, P. – Genovese, M. C. – Gladstein, G., et al.: Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomised, double-blind, placebo controlled, Phase II trial. *Arthritis Rheum*, 2011, 63, s. 939–948.
 - 28 Fischer, J. A. A. – Huebere, A. J. – Wilson, S., et al.: Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. *Arthritis Rheumatol*, 2015, 67, s. 51–62.
 - 29 Mease, P. J. – Goffe, B. S. – Metz, J., et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. *Lancet*, 2000, 356, s. 3853–3890.
 - 30 Antoni, C. E. – Kavanaugh, A. – Kirkham, B., et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). *Arthritis Rheum*, 2005, 52, s. 1227.
 - 31 Mease, P. J. – Kivitz, A. J. – Burch, F. X., et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. *Arthritis Rheum*, 2004, 50, s. 2264–2272.
 - 32 Antoni, C. – Krueger, G. G. – de Vlam, K., et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. *Ann Rheum Dis*, 2005, 64, s. 1150, doi: 10.1136/ard.2004.032268.
 - 33 Mease, P. J. – Kivitz, A. J. – Burch, F. X., et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. *Arthritis Rheum*, 2004, 50, s. 2264–2272.
 - 34 Mease, P. J. – Gladman, D. D. – Ritchlin, C. T., et al.: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum*, 2005, 52, s. 3279.
 - 35 Kavanaugh, A. – Krueger, G. G. – Beutler, A., et al.: Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. *Ann Rheum Dis*, 2007, 66, s. 498–505.
 - 36 Mease, P. J., et al.: LB0001 – Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double blind randomized placebocontrolled study (RAPIDPSA). ELUAR, Berlin, Německo, 8. 6. 2012.
 - 37 Wilsman-Theis, D. – Fronhoffs, K. – Ehler, L. K., et al.: Low-dose methotrexate – a therapeutic kick in TNF-alpha antagonist treatment for recalcitrant psoriasis vulgaris. *Dermatologic Therapy*, 2014, s. 55–59.
 - 38 Kavanaugh, A. – van der Heijde, D. – Beutler, A., et al.: Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: Results through 5 years of a randomized, placebo-controlled study. *Arthritis Care Res*, 2016, 68, s. 267–274.
 - 39 Fagerli, K. M. – Lie, E. – van der Heijde, D., et al.: The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. *Ann Rheum Dis*, 2014, 73, s. 132–137.

Nové poznatky při dávkování metotrexátu v léčbě revmatoidní artritidy

MUDr. Radka Moravcová Revmatologický ústav, Praha

- 1 Andersen, P. A. – West, S. G. – O'Dell, J. R., et al.: Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in randomized, double-blind study. *Ann Intern Med*, 1985, 103, s. 489–496.
- 2 Weinblatt, M. E. – Coblyn, J. S. – Fox, D. A., et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. *N Engl J Med*, 1985, 312, s. 818–822.
- 3 Thompson, R. N. – Watts, C. – Edelman, J., et al.: A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. *J Rheumatol*, 1984, 11, s. 760–763.
- 4 Williams, H. J. – Wilkens, R. F. – Samuelson, C. O. jr., et al.: Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. *Arthritis Rheum*, 1985, 28, s. 721–730.
- 5 Kremer, J. M.: Safety, efficacy and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow up after a mean of 13.3 years. *Arthritis Rheum*, 1997, 40, s. 984–985.
- 6 Weinblatt, M. E. – Kaplan, M. – Germain, B. F., et al.: Methotrexate in rheumatoid arthritis: a five-year prospective multicentre study. *Arthritis Rheum*, 1994, 37, s. 1492–1498.
- 7 Wluka, A. – Buchbinder, R. – Mylvaganam, A., et al.: Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice. *J Rheumatol*, 2000, 27, s. 1864–1871.
- 8 Kremer, J. M. – Phelps, C. T.: Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. *Arthritis Rheum*, 1992, 35, s. 138–145.
- 9 Sany, J. – Anaya, J. M. – Lussiez, V., et al.: Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. *J Rheumatol*, 1991, 18, s. 1323–1327.
- 10 Smolen, J. S. – Landewe, R. – Breedveld, F. C., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis*, 2014, 73, s. 492–509.
- 11 Saag, K. G. – Teng, G. G. – Patkar, N. M., et al.: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum*, 2008, 59, s. 762–784.
- 12 Cronstein, B. N. – Merrill, J. T.: Mechanism of the effects of methotrexate. *Bull Rheum Dis*, 1996, 45, s. 6–8.
- 13 Cutolo, M. – Bossi, A. – Sulli, A., et al.: Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (http-1) but not on synovial macrophages from patients with rheumatoid arthritis. *J Rheumatol*, 2000, 27, s. 2551–2557.
- 14 Swierkot, J. – Szechinski, J.: Methotrexate in rheumatoid arthritis. *Pharmacol Rep*, 2006, 58, s. 473–492.
- 15 Lebbe, C. – Beyler, C. H. – Gerber, N.: Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in RA. *Ann Rheum Dis*, 1994, 53, s. 475–477.
- 16 Balis, F. M. – Mirro, J. jr. – Reagan, G. H., et al.: Pharmacokinetics of subcutaneous methotrexate. *J Clin Oncol*, 1988, 6, s. 1882–1886.
- 17 Hoekstra, M. – Haagsma, C. – Neef, C., et al.: Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. *J Rheumatol*, 2004, 31, s. 645–648.
- 18 Rutkowska-Sak, L. – Rell-Bakalarska, M. – Lisowska, B.: Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. *Reumatologia*, 2009, 47, s. 207–211.
- 19 Mouterde, G. – Baillet, A. – Gaujoux-Viala, C., et al.: Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review. *Joint Bone Spine*, 2011, 78, s. 587–592.
- 20 Tugwell, P. – Bennett, K. – Gent, M.: Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy and safety. *Ann Intern Med*, 1987, 107, s. 358–366.
- 21 Baton, J. M. – Martin, R. W. – Fleischmann, R. M., et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. *N Engl J Med*, 2000, 343, s. 1586–1593.
- 22 Drosos, A. A. – Tsifetaki, N. – Tsiakou, E. K., et al.: Influence of methotrexate on radiological progression in rheumatoid arthritis: a sixty-month prospective study. *Clin Exp Rheumatol*, 1997, 15, s. 263–267.
- 23 Jeurissen, M. E. – Boerbooms, A. M. – van de Putte, L. B., et al.: Influence of methotrexate and azathioprine on radiological progression in rheumatoid arthritis. A randomized, double-blind study. *Ann Intern Med*, 1991, 114, s. 999–1004.
- 24 Emery, P. – Breedveld, F. C. – Lemmel, E. M., et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. *Rheumatology (Oxford)*, 2000, 39, s. 655–665.
- 25 Neuwoss, M. E. – Boerbooms, A. M. – van de Putte, L. B., et al.: Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. *Arthritis Rheum*, 1991, 34, s. 961–972.
- 26 Aletaha, D. – Smolen, J. S.: Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatics drugs for rheumatoid arthritis. An observational study. *J Rheumatol*, 2002, 29, s. 1631–1638.
- 27 Strand, V. – Cohen, S. – Sherif, M., et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. *Arch Intern Med*, 1999, 159, s. 2542–2550.
- 28 Romão, V. C., et al.: Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? *BMC Medicine*, 2013, 11, s. 17.
- 29 Lambert, C. M. – Sandhu, S. – Lochhead, A., et al.: Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. *Arthritis Rheum*, 2004, 50, s. 364–371.
- 30 Visser, K. – Katchamart, W. – Loza, E., et al.: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. *Ann Rheum Dis*, 2009, 68, s. 1086–1093.
- 31 Visser, K. – van der Heijde, D.: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. *Ann Rheum Dis*, 2009, 68, s. 1094–1099.
- 32 Cipriani, P. – Ruscitti, P. – Carubbi, F., et al.: Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. *Clin Ther*, 2014, 36, s. 427–435.
- 33 Braun, J. – Kästner, P. – Flaxenberg, P., et al.: The clinical efficacy and safety of subcutaneous versus oral application of methotrexate in patients with active rheumatoid arthritis (abstrakt). *Ann Rheum Dis*, 2006, 65, s. 87.
- 34 Braun, J. – Kästner, P. – Flaxenberg, P., et al.: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. *Arthritis Rheum*, 2008, 58, s. 73–81.
- 35 Yazici, Y. – Bata, Y.: Parenteral methotrexate for the treatment of rheumatoid arthritis. *Bull Hosp Jt Dis*, 2013, 71, s. 46–48.
- 36 Islam, M. S. – Haq, S. A. – Islam, M. N., et al.: Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. *Mymensingh Med J*, 2013, 22, s. 483–488.
- 37 Jundt, J. W. – Browe, B. A. – Fiocco, G. P., et al.: A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. *J Rheumatol*, 1993, 20, s. 1845–1849.
- 38 Brooks, P. J. – Spruill, W. J. – Parish, R. C., et al.: Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. *Arthritis Rheum*, 1990, 33, s. 91–94.
- 39 Artur, V. – Jung, R. – Homer, D.: A study of parenteral use of methotrexate in rheumatic conditions. *J Clin Nurs*, 2002, 11, s. 256–263.
- 40 Artur, A. B. – Klinkhoff, A. V. – Teufel, A.: Safety of self-injection of gold and methotrexate. *J Rheumatol*, 2001, 26, s. 302–305.
- 41 Malik, F. – Ranganathan, P.: Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. *Pharmacogenomics*, 2013, 14, s. 305–314.
- 42 Bakker, M. F. – Jacobs, J. W. – Welsing, P. M., et al.: Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. *Ann Rheum Dis*, 2010, 69, s. 1849–1852.
- 43 Kremer, J. M. – Davies, J. M. – Rynes, R. I., et al.: Every-other-week methotrexate in patients with rheumatoid arthritis. A double-blind, placebo-controlled prospective study. *Arthritis Rheum*, 1995, 38, s. 601–607.
- 44 Luis, M. – Pacheco-Tena, C. – Cazarin-Barrientos, J., et al.: Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study. *Arthritis Rheum*, 1999, 42, s. 2160–2165.
- 45 Wikske K. A. – Healy, L. A.: Remodelling the pyramid – a concept whose time has come. *J Rheumatol*, 1989, 16, s. 565–567.
- 46 Tugwell, P. – Bennet, K. – Bell, M., et al.: Methotrexate in RA. *Ann Intern Med*, 1989, 110, s. 581–583.
- 47 Kremer, J. M. – Caldwell, J. R. – Cannon, G. W., et al.: The combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who failing on MTX treatment alone. *Arthritis Rheum*, 2000, 43, s. 224.
- 48 O'Dell, J. O. – Haire, C. E. – Ericsson, N., et al.: Treatment of rheumatoid arthritis with methotrexate alone sulphasalazine and

- hydroxychloroquine, or a combination of three medications. *N Engl J Med*, 1996, 334, s. 1287–1291.
- 49 Boers, M. – Verhoeven, A. C. – Markusse, H. M., et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *Lancet*, 1997, 350, s. 309–318.
- 50 Proudman, S. M. – Conaghan, P. G. – Richardson, C., et al.: Treatment of poor prognosis early rheumatoid arthritis. *Arthritis Rheum*, 2000, 43, s. 1809–1819.
- 51 Möttönen, T. – Hanonen, P. – Leirisalo-Repo, M., et al.: Comparison of combination therapy with single therapy in early rheumatoid arthritis. *Lancet*, 1999, 353, s. 1568–1573.
- 52 Dougados, M. – Domne, B. – Cantagrel, A., et al.: Combination therapy in early rheumatoid arthritis. *Ann Rheum Dis*, 1999, 58, s. 220–225.
- 53 Furst, D. – Breedveld, F. C. – Kalden, J. R., et al.: Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2002). *Ann Rheum Dis*, 2003, 62, s. ii2–ii19.
- 54 Malgarini, R. B. – Pimpinella, G.: Etanercept and methotrexate in rheumatoid arthritis. *Lancet*, 2004, 363, s. 1733.
- 55 Emery, P. – Breedveld, F. C. – Hall, S., et al.: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. *Lancet*, 2008, 372, s. 375–382.
- 56 Maini, R. N. – Breedveld, F. C. – Kalden, J. R., et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. *Arthritis Rheum*, 1998, 41, s. 1552–1563.
- 57 Breedveld, F. C. – Weisman, M. H. – Kavanaugh, A. F., et al.: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum*, 2006, 54, s. 26–37.
- 58 Keystone, E. C. – Breedveld, F. C. – van der Heijde, D., et al.: Long-term effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. *J Rheumatol*, 2014, 41, s. 5–14.
- 59 Keystone, E. C. – Genovese, M. C. – Klareskog, L., et al.: Golimumab, a human antibody to tumour necrosis factor [alpha] given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. *Ann Rheum Dis*, 2009, 68, s. 789–796.
- 60 van der Heijde, D. – Klareskog, L. – Rodriguez-Valverde, V., et al.: Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis Rheum*, 2006, 54, s. 1063–1074.
- 61 Smolen, J. S. – Landewé, R. B. – Mease, P., et al.: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. *Ann Rheum Dis*, 2009, 68, s. 797–804, doi: 10.1136/ard.2008.101659.
- 62 Keystone, E. – Heijde, D. V. – Mason, D. jr., et al.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum*, 2008, 58, s. 3319–3329.
- 63 Fleischmann, R. – Vencovsky, J. – van Vollenhoven, R. F., et al.: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. *Ann Rheum Dis*, 2009, 68, s. 805–811.
- 64 St Clair, E. W. – van der Heijde, D. M. – Smolen, J. S., et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis Rheum*, 2004, 50, s. 3432–3443.
- 65 Weinblatt, M. E. – Fleischmann, R. – Huizinga, T. W., et al.: Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. *Rheumatology* (Oxford), 2012, 51, s. 2204–2214.
- 66 Emery, P. – Fleischmann, R. – van der Heijde, D., et al.: The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. *Arthritis Rheum*, 2011, 63, s. 1200–1210.
- 67 Klareskog, L. – van der Heijde, D. – de Jager, J. P., et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet*, 2004, 363, s. 675–681.
- 68 van der Heijde, D. – Klareskog, L. – Landewé, R., et al.: Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum*, 2007, 56, s. 3928–3939.
- 69 Keystone, E. C. – Kavanaugh, A. F. – Sharp, J. T., et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis Rheum*, 2004, 50, s. 1400–1411.
- 70 Maini, R. N. – Breedveld, F. C. – Kalden, J. R., et al.: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. *Arthritis Rheum*, 2004, 50, s. 1051–1065.
- 71 Lipsky, P. E. – van der Heijde, D. M. – St Clair, E. W., et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. *N Engl J Med*, 2000, 343, s. 1594–1602.
- 72 Weinblatt, M. E. – Keystone, E. C. – Furst, D., et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking methotrexate. The ARMADA trial. *Arthritis Rheum*, 2003, 48, s. 35–45.
- 73 Weinblatt, M. E. – Keystone, E. C. – Furst, D., et al.: Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. *Ann Rheum Dis*, 2006, 65, s. 753–759.
- 74 Smolen, J. S. – Han, C. – Bala, M., et al.: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed sub-analysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. *Arthritis Rheum*, 2005, 52, s. 1020–1030.
- 75 Edwards, J. C. – Szczepanski, L. – Szechinski, J., et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med*, 2004, 350, s. 2572–2581.
- 76 Chatzidionysiou, K. – Lie, E., et al.: Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. *Ann Rheum Dis*, 2012, 71, s. 374–377.
- 77 Buckley, F. – Finckh, A. – Huizinga, T. W. J., et al.: Comparative efficacy of biologics as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional dmards: a network meta-analysis. *Arthritis Rheum*, 2012, 64, s. 918.
- 78 Burmester, G. R. – Rigby, W. F. – van Vollenhoven, R. F., et al.: Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. *Ann Rheum Dis*, 2016, 75, s. 1081–1091.
- 79 Velagapudi, R. B. – Noerterseuser, P. A. – Awini, W. M., et al.: Effect of methotrexate (MTX) coadministration on the pharmacokinetics (PK) of adalimumab (HUMIRA, Abbott), following a single intravenous (iv) injection. *Arthritis Rheum*, 2003, 48, s. S141.
- 80 Weisman, M. H. – Moreland, L. W. – Furst, D. E., et al.: Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. *Clin Ther*, 2003, 25, s. 1700–1721.
- 81 Bartelds, G. M. – Krieckaert, C. L. – Nurmohamed, M. T., et al.: Development of anti-drug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. *JAMA*, 2011, 305, s. 1460–1468.
- 82 Furst, D. E. – Inoue, E. – Tahala, E., et al.: Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. *J Rheumatol*, 1989, 16, s. 536–543.
- 83 Mielants, H. – Veyts, E. M. – Van der Straeten, C., et al.: The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: an open prospective study. *J Rheumatol*, 1991, 18, s. 978–983.
- 84 Cronstein, B. N.: Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. *Pharmacol Rev*, 2005, 57, s. 163–172.
- 85 Yamanaka, H. – Inoue, E. – Tahala, E., et al.: Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). *Mod Rheumatol*, 2007, 17, s. 98–105.
- 86 Takeuchi, T. – Yamanaka, H. – Ishiguro, N., et al.: Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. *Ann Rheum Dis*, 2014, 73, s. 536–543.
- 87 Burmester, G. R. – Kivitz, A. J. – Kuplet, H., et al.: Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. *Ann Rheum Dis*, 2015, 74, s. 1037–1044.
- 88 Kaeley, G. S. – Nishio, M. J. – Goral, J. R., et al.: Changes in ultrasonographic vascularity upon initiation of adalimumab combination therapy in rheumatoid arthritis patients with inadequate response to methotrexate. *Arthritis Rheumatol*, 23. 5. 2016, doi: 10.1002/art.39751, Epub před tiskem.
- 89 Visser, K. – Katchamart, W. – Loza, E., et al.: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. *Ann Rheum Dis*, 2009, 68, s. 1086–1093.

Biosimilars – co je nového?

MUDr. Šárka Forejtová Revmatologický ústav, Praha

- 1 Al-Sabbagh, A. – Olech, E. – McClellan, J. E., et al.: Development of biosimilars. *Semin Arthritis Rheum*, 21. 1. 2016, pii: S0049-0172(16)00028-7, doi: 10.1016/j.semarthrit.2016.01.002, publikováno online.
- 2 Dörner, T. – Kay, J.: Biosimilars in rheumatology: current perspectives and lessons learnt. *Nat Rev Rheumatol*, 2015, 11, s. 713–724.
- 3 Dörner, T. – Strand, V. – Cornes, P., et al.: The changing landscape of biosimilars in rheumatology. *Ann Rheum Dis*, 8. 3. 2016, publikováno online.
- 4 GaBi-Online: FDA approves infliximab biosimilar Inflectra. Dostupné z: <http://www.gabionline.net/Biosimilars/News/FDA-approves-infliximab-biosimilar-Inflectra>, vyhledáno 23. 6. 2016.
- 5 Yoo, D. H. – Hrycaj, P. – Miranda, P., et al.: A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. *Ann Rheum Dis*, 2013, 72, s. 1613–1620.
- 6 Park, W. – Hrycaj, P. – Jeka, S., et al.: A randomised, double-blind, multicentre, parallel group, prospective study comparing the pharmacokinetics, safety and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. *Ann Rheum Dis*, 2013, 72, s. 1605–1612.
- 7 Park, W. – Miranda, P. – Brzosko, M., et al.: Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: Comparison between continuing with CT-P13 and switching from infliximab to CT-P13. Prezentováno na ACR 2013, abstrakt L15.
- 8 Taylor, P.: A scientific update on biosimilar infliximab (CT-P13) in rheumatic disease. *Expert Rev Clin Immunol*, 2015, 11, s. S1–S4.
- 9 Baji, P. – Péntek, M. – Szanto, S., et al.: Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and metaanalysis. *Eur J Health Econ*, 2014, 15, s. S45–S52.
- 10 Kay, J., et al.: BOWO15, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses: 54-week results of randomised, double blind, active comparator study. *Arthritis Rheum*, 2014, abstrakt L20.
- 11 Choe, J. Y. – Prodanovic, N. – Niebrzydowski, J., et al.: A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. *Ann Rheum Dis*, 28. 8. 2015, pii: annrheumdis-2015-207764, doi: 10.1136/annrheumdis-2015-207764, publikováno online.
- 12 Bae, S. C. – Kim, J. – Choe, J. Y.: HERA Study Investigators. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. *Ann Rheum Dis*, 23. 2. 2016, pii: annrheumdis-2015-207613, doi: 10.1136/annrheumdis-2015-207613, publikováno online.
- 13 Emery, P. – Vencovsky, J. – Sylwestrzak, A., et al.: A phase III randomised, double blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. *Ann Rheum Dis*, 6. 7. 2015, pii: annrheumdis-2015-207588, doi: 10.1136/annrheumdis-2015-207588, publikováno online.
- 14 Jani, R. H. – Gupta, R. – Bhatia, G., et al.: A prospective, randomised, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia;

- ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. *Int J Rheum Dis*, 14, 7. 2015, doi: 10.1111/1756-185X.12711, publikováno online.
- 15 **Olech, E.** – Biosimilars: Rationale and current regulatory landscape. *Semin Arthr Rheum*, 2016, 45, s. S1–S10.
- 16 GaBi-Online: Finnish drug regulator recommends interchangeability of similars. Dostupné z: <http://www.gabionline.net/Policies-Legislation/Finnish-drug-regulator-recommends-interchangeability-of-biosimilars>, vyhledáno 29. 5. 2015.
- 17 GaBi-Online: German physicians not pressured to switch to biosimilar *infiximab*. Dostupné z: <http://www.gabionline.net/Reports/German-physicians-not-pressured-to-switch-to-biosimilar-infiximab>, vyhledáno 2. 10. 2015.
- 18 GaBi-Online: Biosimilars in UK gain NICE recommendation. Dostupné z: <http://www.gabionline.net/Policies-Legislation/Biosimilars-in-UK-gain-NICE-recommendation>, vyhledáno 23. 6. 2016.
- 19 GaBi-Online: BSG guidance recommends switching to biosimilar *infiximab*. Dostupné z: <http://www.gabionline.net/Guidelines/BSG-guidance-recommends-switching-to-biosimilar-infiximab>, vyhledáno 26. 2. 2016.
- 20 GaBi-Online: Price/access expected to be major drivers for biosimilars uptake. Dostupné z: <http://www.gabionline.net/Reports/Price-access-expected-to-be-major-drivers-for-biosimilars-uptake>, vyhledáno 23. 6. 2016.
- 21 **Weise, M.** – **Kurki, P.** – **Wolf-Holz, E.**, et al.: Biosimilars: the science of extrapolation. *Blood*, 2014, 124, s. 3191–3196.
- 22 **Pavelka, K.** – **Jarošová, K.** – **Suchý, D.** – **Uher, M.** – **Hejduk, K.**: První zkušenosti s biosimilárním infliximabem CT-P13 u nemocných se závažnými revmatickými onemocněními v České republice v národním registru ATTRA. *Čes Revmatol*, 2016, 24, s. 15–30.

Hodnocení magnetické rezonance u non-radiografické axiální spondyloartritidy

MUDr. Kristýna Grobelná | MUDr. Michal Tomčík, Ph.D. | prof. MUDr. Karel Pavelka, DrSc.
Revmatologický ústav, Praha

- 1 **Rudwaleit, M.** – **Khan, M. A.** – **Sieper, J.**: The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? *Arthritis and rheumatism*, 2005, 52, s. 1000–1008.
- 2 **Boonen, A.** – **Brinkhuizen, T.** – **Landewe, R.**, et al.: Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. *Annals of the rheumatic diseases*, 2010, 69, s. 1123–1128.
- 3 **Rudwaleit, M.** – **Braun, J.** – **Sieper, J.**: Assessment of SpondyloArthritis international Society [ASAS classification criteria for axial spondyloarthritis]. *Zeitschrift für Rheumatologie*, 2009, 68, s. 591–593.
- 4 **Baraliakos, X.** – **Braun, J.**: Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? *RMD Open*, 2015, 1, e000053, doi: 10.1136/rmdopen-2015-000053. eCollection 2015.
- 5 **Rudwaleit, M.** – **Haibel, H.** – **Baraliakos, X.**, et al.: The early disease stage in axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. *Arthritis and rheumatism*, 2009, 60, s. 717–727.
- 6 **Mandl, P.** – **Navarro-Compán, V.** – **Terslev, L.**, et al.: EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. *Ann Rheum Dis*, 2014, doi:10.1136/annrheumdis-2014-206971.
- 7 **Sieper, J.** – **Rudwaleit, M.** – **Baraliakos, X.**, et al.: The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. *Annals of the rheumatic diseases*, 2009, 68, s. ii1–44.
- 8 **Rudwaleit, M.** – **Jurik, A. G.** – **Hermann, K. G.**, et al.: Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. *Annals of the rheumatic diseases*, 2009, 68, s. 1520–1527.
- 9 **Jans, L.** – **Van Praet, L.** – **Elewaut, D.**, et al.: MRI of the SI joints commonly shows non-inflammatory disease in patients clinically suspected of sacroiliitis. *European Journal of Radiology*, 2014, 83, s. 179–184.
- 10 **Althoff, C. E.** – **Feist, E.** – **Burova, E.**, et al.: Magnetic resonance imaging of active sacroiliitis: Do we really need gadolinium? *European Journal of Radiology*, 2009, 71, s. 232–236.
- 11 **Mitra, R.**: Osteitis Condensans Il. *Rheumatology international*, 2009, 30, s. 293–296.
- 12 **Weber, U.** – **Pedersen, S. J.** – **Østergaard, M.**, et al.: Can erosions on MRI of the sacroiliac joints be reliably detected in patients with ankylosing spondylitis? A cross-sectional study. *Arthritis Res Ther*, 2012, 14, s. R124, doi: 10.1186/ar3854.
- 13 **Rudwaleit, M.** – **Claudepierre, P.** – **Wordsworth, P.**, et al.: Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. *The Journal of rheumatology*, 2009, 36, s. 801–808.
- 14 **Sieper, J.** – **van der Heijde, D.** – **Dougados, M.**, et al.: Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). *Annals of the rheumatic diseases*, 2013, 72, s. 815–822.

Suplementace kalcíem a vitamínem D při zahájení léčby glukokortikoidy

MUDr. Olga Růžičková Revmatologický ústav, Praha

- 1 **Overman, R. A.** – **Yeh, J.** – **Chad L.** – **Deal, Ch. J.**: Prevalence of oral glucocorticoid usage in the United States: A general population perspective. *Arthritis Care Research*, 2013, 65, s. 294–298.
- 2 **Canalis, E.** – **Mazziotti, G.** – **Gustina, A.** – **Bilezikian, J. P.**: Glucocorticoid-induced osteoporosis: pathophysiology and therapy. *Osteoporos Int*, 2007, 18, s. 1319–1328.
- 3 **Steinbuch, M.** – **Youket, T. E.** – **Cohen, S.**: Oral glucocorticoid use is associated with an increased risk of fracture. *Osteoporos Int*, 2004, 15, s. 323–328.
- 4 **van Staa, T. P.** – **Leufkens, H. G.** – **Abenham, L.**, et al.: Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. *Rheumatology (Oxford)*, 2000, 39, s. 1383–1389.
- 5 **van Staa, T. P.** – **Leufkens, H. G.** – **Abenham, L.**, et al.: Use of oral corticosteroids and risk of fractures. *J Bone Miner Res*, 2000, 15, s. 993–1000.
- 6 **van Staa, T. P.** – **Leufkens, H. G.** – **Cooper, C.**: The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. *Osteoporos Int*, 2002, 13, s. 777–787.
- 7 **van Staa, T. P.** – **Leufkens, H. G.** – **Cooper, C.**: Use of inhaled corticosteroids and risk of fractures. *J Bone Miner Res*, 2001, 16, s. 581–588.
- 8 **Kroger, H.** – **Honkanen, R.** – **Saarikoski, S.** – **Alhava, E.**: Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis – a population based study. *Ann Rheum Dis*, 1994, 53, s. 18–23.
- 9 **Adachi, J. D.** – **Papaioannou, A.**: In whom and how to prevent glucocorticoid-induced osteoporosis. *Best Pract Res Clin Rheumatol*, 2005, 19, s. 1039–1064.
- 10 **Geusens, P.** – **van Brusel, M. S.** – **Lems, W. F.**: Osteoporosis and fracture risk: pathogenesis, epidemiology, clinical aspects and diagnosis. *EULAR Compendium on Rheumatic Diseases*, 2009.
- 11 **van Staa, T. P.** – **Leufkens, H. G.** – **Abenham, L.**, et al.: Use of oral corticosteroids and risk of fractures. *J Bone Miner Res*, 2000, 15, s. 993–1000.
- 12 **Compston, J. E.**: Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. *Curr Rheumatol Rep*, 2007, 9, s. 78–84.
- 13 **Ringe, J. D.** – **Faber, H.**: Calcium and vitamin D in the prevention and treatment of glucocorticoid-induced osteoporosis. *Clin Exp Rheumatol*, 2000, 18 (dopl. 21), s. 44–48.
- 14 **Silvermann, S.** – **Curtis, J.** – **Saag, K.**: International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. *Osteoporos Int*, 2015, 26, s. 419–420.
- 15 **Matkovic, V.** – **Heaney, R. P.**: Calcium balance during human growth: Evidence for threshold behavior. *Am J Clin Nutr*, 1992, 55, s. 992–996.
- 16 **Dawson-Hughes, B.** – **Dallal, G. E.** – **Krall, E. A.**, et al.: A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. *N Engl J Med*, 1990, 323, s. 878–883.
- 17 **Reid, R.** – **Ibbertson, H. K.**: Calcium supplements in the prevention of steroid-induced osteoporosis. *Amer J Clin Nutr*, 1986, 44, s. 287–290.
- 18 **Sambrook, P.** – **Birmingham, J.** – **Kelly, P.**, et al.: Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. *N Engl J Med*, 1995, 328, s. 1747–1752.
- 19 **Adachi, J. D.** – **Bensen, W. G.** – **Brown, J.**, et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. *N Engl J Med*, 1997, 337, s. 382–387.
- 20 **Roux, C.** – **Oriente, P.** – **Laan, R.**, et al.: Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. *J Clin Endocrinol Metab*, 1998, 83, s. 1128–1133.
- 21 **Cohen, S.** – **Levy, R. M.** – **Keller, M.**, et al.: Risedronate therapy prevents corticosteroid induced bone loss. A twelve-month, multicenter, randomized, double-blind, placebo controlled, parallel-group study. *Arthritis Rheum*, 1999, 42, s. 2309–2318.
- 22 **Pliz, S.** – **März, W.** – **Wellnitz, B.**, et al.: Vitamin D deficiency and heart failure. *J Clin Endocrinol Metab*, 2008, 93, s. 3927–3935.
- 23 **Hahn, T. J.** – **Hahn, B. H.**: Osteopenia in subjects with rheumatic diseases: Principles of diagnosis and therapy. *Semin Arthritis Rheum*, 1976, 6, s. 65–88.
- 24 **Hahn, T. J.** – **Halstead, L. R.** – **Teitelbaum, S. L.** – **Hahn, B. H.**: Altered mineral metabolism in glucocorticoid-induced osteopenia: Effect of 25-hydroxyvitamin D administration. *J Clin Invest*, 1979, 64, s. 655–665.
- 25 **Lane, N. E.** – **Genant, H. K.** – **Kiney, J. H.** – **Englemann, E.**: Effect of intermittent cyclic etidronate (ICT) therapy for glucocorticoid-induced osteoporosis in rheumatoid arthritis (RA): Interim analysis. *J Bone Miner Res*, 1993, 8, s. S262.
- 26 **Pitt, P.** – **Li, F.** – **Macintosh, C.**: A double-blind placebo-controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term corticosteroid treatment. *J Bone Miner Res*, 1997, 12, s. S510.
- 27 **Poubelle, P. E.** – **Adachi, J. D.** – **Hawkins, F.**: Alendronate increases bone mineral density in patients on glucocorticoid therapy: Results of the multinational study. *Arthritis Rheum*, 1997, 40, s. S327.
- 28 **Adachi, J. D.** – **Ioannidis, G.**: Calcium and vitamin D therapy in corticosteroid-induced bone loss: What is the evidence? *Calcif Tissue Int*, 1999, 65, s. 332–336.
- 29 **Lund, B.** – **Andersen, R. B.** – **Trios, T.**, et al.: Effect of 1-alpha-hydroxy vitamin D3 and 1,25-dihydroxy vitamin D3 on intestine and bone in glucocorticoid-treated patients. *Clin Endocrinol*, 1977, 7, s. 177–181.
- 30 **Ringe, J. D.**: Active vitamin D metabolites in glucocorticoid-induced osteoporosis. *Calcif Tissue Int*, 1997, 60, s. 124–127.
- 31 **Tsurukami, H.** – **Nakamura, T.** – **Suzuki, I. K.**, et al.: A novel synthetic vitamin D analogue, 2ß-(3-hydroxypropoxy) 1,25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. *Calcif Tissue Int*, 1994, 54, s. 142–149.
- 32 **Shiraishi, A.** – **Takeda, S.** – **Masaki, T.**, et al.: Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. *J Bone Miner Res*, 2000, 15, s. 770–779.
- 33 **Dykman, T. R.** – **Haralson, K. M.** – **Gluck, O. S.**, et al.: Effect of oral

- 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. *Arthritis Rheum*, 1984, 27, s. 1336–1343.
- 34 Neuhaus, R. – Lohmann, R. – Platz, K. P., et al.: Treatment of osteoporosis after liver transplantation. *Transplant Proc*, 1995, 27, s. 1226–1227.
- 35 Sambrook, P. – Marshall, G. – Henderson, K., et al.: Effect of calcitriol in the prevention of bone loss after cardiac or lung transplantation. *J Bone Miner Res*, 1997, 12, dopl. 1, s. S400.
- 36 Graf, H. – Tummvoll, H. K. – Kovarik, J., et al.: Aktive Vitamin-D-Metabolite in der Therapie der Cortisonosteoporose. *Wiener Klin Wschr*, 1980, 92, s. 776–777.
- 37 Braun, J. J. – Birkenhager-Frenkel, D. H. – Rietveld, A. H., et al.: Influence of alpha-(OH) D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; A double blind controlled study. *Clin Endocrinol*, 1983, 18, s. 265–273.
- 38 Schaadt, O. P. – Bohr, H. H.: Alfacalcidol in prednisone treatment. A controlled study of effect on bone mineral content in lumbar spine, femoral neck and shaft. *Calcif Tissue Int*, 1986, 39, dopl., s. A58.
- 39 Verstraeten, A. – Dequurki, J. – Nijs, J., et al.: Prevention of postmenopausal bone loss in rheumatoid arthritis patients. A two-year prospective study. *Clin Exp Rheumatol*, 1989, 7, s. 351–358.
- 40 Yamada, H.: Long-term effect of alpha-hydroxy vitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosis. *Nippon Naibunpi Gakkai Zasshi*, 1989, 65, s. 603–614.
- 41 Van Cleemput, J. – Daenen, W. – Geusens, P., et al.: Prevention of bone loss in cardiac transplant recipients. *Transplantation*, 1996, 61, s. 1495–1499.
- 42 Lakatos, P. – Kiss, L. – Horvath, C., et al.: Prevention of corticosteroid-induced osteoporosis with alfacalcidol. *Lege Artis Medicinae*, 1996, 6, s. 624–629.
- 43 Reginster, J. Y. – Kuntz, D. – Verdickt, W., et al.: Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. *Osteoporos Int*, 1999, 9, s. 75–81.
- 44 Chapuy, M. C. – Arlot, M. E. – Duboef, F., et al.: Vitamin D3 and calcium to prevent hip fractures in elderly women. *N Engl J Med*, 1992, 327, s. 1637–1642.
- 45 Dawson-Huges, B. – Harris, S. S. – Krall, E. A. – Dallal, G. E.: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. *N Engl J Med*, 1997, 337, s. 670–676.
- 46 Francis, R. M. – Boyle, I. T. – Moniz, C., et al.: A comparison of the effects of alfacalcidol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures. *Osteoporos Int*, 1996, 6, s. 284–290.
- 47 Ringe, J. D. – Coster, A. – Meng, T., et al.: Treatment of glucocorticoid induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. *Calcif Tissue Int*, 1999, 63, s. 337–340.
- 48 Bischoff-Ferrari, H. A., et al.: Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *J Bone Miner Res*, 2004, 19, s. 265–269.
- 49 Sambrook, P. N. – Kotowicz, M. – Nash, P.: Prevention and treatment of glucocorticoid induced osteoporosis: A comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. *J Bone Miner Res*, 2003, 18, s. 919–924.
- 50 Rizzoli, R. – von Tscharner, V. – Fleisch, H.: Increase of adenylate cyclase catalytic-unit activity by dexamethasone in rat osteoblast-like cells. *Biochem J*, 1986, 237, s. 447–454.
- 51 Canalis, E. – Mazziotti, G. – Gustina, A., et al.: Glucocorticoid-induced osteoporosis: pathophysiology and therapy. *Osteoporos Int*, 2007, 18, s. 1319–1328.
- 52 Weinstein, R. S. – Jilka, R. L. – Parfitt, A. M. – Manolagas, S. C.: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. *J Clin Invest*, 1998, 102, s. 274–282.
- 53 Weinstein, R. S.: Glucocorticoid-induced osteoporosis. In: MR ASB (ed): *Primer on the metabolic bone diseases and disorders of mineral metabolism*. John Wiley & Sons, Hoboken, 2009, NJ, doi:10.1002/9780470623992.ch58.
- 54 Rochefort, G. Y. – Pallu, S. – Benhamou, C. L.: Osteocyte: the unrecognized side of bone tissue. *Osteoporos Int*, 2010, 21, s. 1457–1469.
- 55 Den Uyl, D. – Bultink, I. E. – Lems, W. F.: Advances in glucocorticoid-induced osteoporosis. *Curr Rheumatol Rep*, 2011, 13, s. 233–240.
- 56 Hayashi, K. – Yamaguchi, T. – Yano, S., et al.: BMPA Vnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. *Biochem Biophys Res Commun*, 2009, 379, s. 261–266.
- 57 Yao, W. – Cheby, Z. – Busse, C., et al.: Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. *Arthritis Rheum*, 2008, 58, s. 1674–1686.
- 58 Cooper, M. S. – Rabbitt, E. H. – Goddard, P. E., et al.: Osteoblastic 11 beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. *J Bone Miner Res*, 2002, 17, s. 979–986.
- 59 Vestergaard, P. – Rejnmark, L. – Mosekilde, L.: Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. *Calcif Tissue Int*, 2008, 82, s. 249–257.
- 60 Štěpán, J.: Osteoporóza a metabolická onemocnění skeletu. In: Pavelka, K., et al.: *Revmatologie*. Praha, Maxdorf Jessenius, 2012, s. 483–552.
- 61 Hála, T., et al.: Novinky v léčbě osteoporózy. *Med Pro Praxi*, 2007, 4, s. 454–457.

Lokální terapie ketoprofenem

MUDr. Kateřina Zegulková Revmatologický ústav, Praha

- 1 Mazières, B.: Topical ketoprofen patch. *Drugs RD*, 2005, 6, s. 337–344.
- 2 Derry, S.: Topical NSAIDs for chronic musculoskeletal pain in adults. *Cochrane Database Sys Rev*, 2012, 12, 9, CD007400.
- 3 Derry, S.: Topical NSAIDs for acute musculoskeletal pain in adults. *JAMA Clin Ev Syn*, 2016, s. 813–814.
- 4 Pavelka, K., et al.: *Farmakoterapie revmatických onemocnění*. Grada, 2005, s. 31–37.
- 5 Tanasait, N., et al.: Developments and evaluation of ketoprofen acrylic transdermal patches. *Trop Journal Pharma Res*, 2012, 13, s. 553–560.
- 6 Kawai, S., et al.: Efficacy and safety of ketoprofen patch in patients with rheumatoid arthritis. *J Clin Pharmacol*, 2010, 50, s. 1171–1179.
- 7 Shinkai, N.: Intraarticular penetration of ketoprofen and analgesic effects after topical patch application in rats. *J Control Release*, 2008, 131, s. 107–112.
- 8 Cheby, Y.: Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine dendrimers. *J Pharm Sci*, 2007, 96, s. 595–602.
- 9 Tsukasa, S., et al.: Comparison of the efficacy and skin permeability of topical NSAID preparations used in Europe. *Eur J Pharm Sci*, 2012, 47, s. 890–895.
- 10 Rhee, Y. S.: Transdermal delivery of ketoprofen using microemulsions. *Int J Pharm*, 2001, 228, s. 161–170.
- 11 SÚKL, souhrn údajů o přípravku.
- 12 Komatsu, T., et al.: Comparison of the efficacy and skin permeability of topical NSAID preparations used in Europe. *Eur J Pharm Sci*, 2012, 47, s. 890–895.

Pravděpodobnost setrvání na biologické léčbě u nemocných s revmatoidní artritidou – metaanalýza

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Souto, A. – Maneiro, J. R. – Gomez-Reino, J. J.: Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. *Rheumatology (Oxford)*, 2016, 55, s. 523–534.

Ukončení biologické léčby u osob s revmatoidní artritidou

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Ramiro, S. – Landewe, R. – van der Heijde, D. – Harrison, D. – Collier, D. – Michaud, K.: Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors? *RMD Open*, 2015, 1, e000155.

Mukopolysacharidóza I v revmatologické ambulanci

MUDr. RNDr. Pavel Ješina, Ph.D. Ústav dědičných metabolických poruch 1. LF UK a VFN, Praha

- 1 Poupětová, H. – Ledvinová, J. – Berná, L., et al.: The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. *J Inherit Metab Dis*, 2010, 33, s. 387–396.
- 2 Ješina, P. – Magner, M. – Poupětová, H., et al.: Mukopolysacharidóza I – klinické projevy u 24 dětí z České republiky a Slovenska. *Czecho-Slovak Pediatrics/Cesko-Slovenska Pediatrie*, 2011, 66, s. 6–11.
- 3 Michalik, J. – Valenta, M. – Honzik, T., et al.: Kvalita života osob pečujících o dítě s dědičným metabolickým onemocněním. *Czecho-Slovak Pediatrics / Cesko-Slovenska Pediatrie*, 2012, 67, s. 376–384.
- 4 Malinová V., et al.: Lysosomální onemocnění – současné možnosti diagnostiky a terapie. *Pediatric pro praxi*, 2013, 3, s. 157–160.
- 5 Clarke, L. A. – Hollak, C. E. M.: The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2015, 29, s. 219–235.
- 6 Ješina, P.: Revmatologické projevy u pacientů s mukopolysacharidózou. *Acta Medicinæ*, 2015, 6, s. 78–82.
- 7 Wraith, J. E. – Jones, S.: Mucopolysaccharidosis type I. *Pediatr Endocrinol Rev*, 2014, 12, s. 102–106, recenze.
- 8 Morishita, K. – Petty, R. E.: Musculoskeletal manifestations of mucopolysaccharidoses. *Rheumatology*, 2011, 50, s. 19–25.

Metotrexát v kombinační léčbě revmatoidní artritidy

MUDr. David Suchý, Ph.D. Oddělení klinické farmakologie FN, Plzeň

- 1 Tugwell, P. – Pincus, T. – Yocum, D., et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. *N Engl J Med*, 1995, 333, s. 137–141.
- 2 Hetland, M. – Stengaard-Pedersen, K. – Junker P., et al.: Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis. An investigator-initiated, multicenter, randomised, double blind, parallel group, placebo-controlled study. *Arthritis Rheum*, 2006, 54, s. 1401–1409.
- 3 Kremer, J. M. – Genovese, M. C. – Canon, G. W., et al.: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*, 2002, 137, s. 726–733.
- 4 Chung, G. – Mallon, C. – Spadi, B., et al.: Survival analysis of treatment with leflunomide, combination leflunomide/methotrexate and infliximab for rheumatoid arthritis in routine clinical practise. *Arthritis Rheum*, 2003, 48 (dopl.), abstrakt S793.
- 5 Haagsma, C. J. – Blom, H. J. – Riel, P. L., et al.: Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomised, controlled, double-blind, 52 week clinical trial. *Br J Rheumatol*, 1997, 36, s. 1082–1088.
- 6 Dougados, M. – Combe, B. – Cantagrel, P., et al.: Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. *Ann Rheum Dis*, 1999, 58, s. 220–225.
- 7 Capell, H. A. – Madhok, R. – Porter, D. R., et al.: Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCO study. *Ann Rheum Dis*, 2007, 66, s. 235–241.
- 8 O'Dell, J. R. – Haire, C. E. – Erikson, N., et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. *N Engl J Med*, 1996, 334, s. 1287–1291.
- 9 O'Dell, J. R. – Leff, R. – Paulsen, G., et al.: Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*, 2002, 46, s. 1164–1170.
- 10 Saunders, S. A. – Capall, H. A. – Stirling, A., et al.: Triple therapy in early, active rheumatoid arthritis: a randomised, single blind, controlled trial comparing step up and parallel treatment strategies. *Arthritis Rheum*, 2008, 58, s. 1310–1317.
- 11 van Tuyll, L. H. – Leems, W. – Voskuyl, A. E., et al.: Tight kontrol and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. *Ann Rheum Dis*, 2008, 58, s. 1574–1577.
- 12 Boers, M. – Verhoeven, A. C. – Markusse, H. M., et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *Lancet*, 1997, 350, s. 309–318.
- 13 Verschuren, P. – Cock, D. – Corluy, L., et al.: Methotrexate with other DMARDs is not superior to MTX alone for remission induction with moderate- to high glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment? The CareRA trial. *Ann Rheum Dis*, 2015, 74, s. 27–34.
- 14 Maini, R. – St Clair, E. W. – Breedveld, F., et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. *Lancet*, 1999, 354, s. 1932–1939.
- 15 Weinblatt, M. E. – Keystone, E. C. – Furst, D. E., et al.: Adalimumab, a fully human anti-tumour necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum*, 2003, 48, s. 35–45.
- 16 Breedveld, F. C. – Weisman, M. H. – Kavanaugh, A. F., et al.: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum*, 2006, 54, s. 26–37.
- 17 Weinblatt, M. E. – Kremer, J. M. – Bankhurst, A. D., et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med*, 1999, 340, s. 253–259.
- 18 Moreland, L. W. – O'Dell, J. R. – Paulus, H. E., et al.: A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis Rheum*, 2012, 64, s. 2824–2835.
- 19 Emery, P. – Breedveld, F. C. – Hall, S., et al.: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double blind, parallel treatment trial. *Lancet*, 2008, 372, s. 372–382.
- 20 Keystone, E. – Heijde, D. – Mason, D. Jr., et al.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum*, 2008, 58, s. 3319–3329.
- 21 Smolen, J. – Landewe, R. B. – Mease, P. – Brzezicki, et al.: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. *Ann Rheum Dis*, 2009, 68, s. 797–804.
- 22 Emery, P. – Fleischmann, R. M. – Moreland, L. W., et al.: Golimumab, a human anti-tumour necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. *Arthritis Rheum*, 2009, 60, s. 2272–2283.
- 23 Cohen, S. B. – Emery, P. – Greenwald, M. V., et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. *Arthritis Rheum*, 2006, 54, s. 2793–2806.
- 24 Jones, G. – Sebba, A. – Gu, J., et al.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. *Ann Rheum Dis*, 2010, 69, s. 88–96.
- 25 Smolen, J. S. – Beaulieu, A. – Rubbert-Roth, A., et al.: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTON study): a double-blind, placebo-controlled, randomised trial. *Lancet*, 2008, 371, s. 987–997.
- 26 Fleischmann, R. M. – Halland, A. M. – Brzosko, M., et al.: Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. *J Rheumatol*, 2013, 40, s. 113–126.
- 27 Strand, V. – Burmester, G. R. – Ogale, S., et al.: Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. *Rheumatology (Oxford)*, 2012, 51, s. 1860–1869. Epub 28. 1. 2012.
- 28 Westhovens, R. – Robles, M. – Ximenes, A. C., et al.: Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. *Ann Rheum Dis*, 2009, 68, s. 1870–1877.
- 29 Kremer, J. M. – Genant, H. K. – Moreland, L. W., et al.: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. *Ann Intern Med*, 2006, 144, s. 865–876.
- 30 O'Dell, J. R. – Curtis, J. R. – Mikuls, T. R., et al.: Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. *Arthritis Rheum*, 2013, 65, s. 1985–1994.
- 31 van Vollenhoven, R. F. – Tenorek, P. – Forslund, K., et al.: Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, nonblinded, parallel group Swefot trial. *Lancet*, 2012, 379, s. 1712–1720.
- 32 O'Dell, J. R. – Mikuls, T. R. – Taylor, T. H., et al.: Therapies for active rheumatoid arthritis after methotrexate failure. *N Engl J Med*, 2013, 369, s. 307–318.
- 33 Burmester, G. R. – Rigby, W. F. – van Vollenhove, R. F., et al.: Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. *Ann Rheum Dis*, 2016, 75, s. 1081–1091, doi:10.1136/annrheumdis-2015-207628.

Prolia – dlouhodobě účinná a bezpečná léčba postmenopauzální osteoporózy

prof. MUDr. Pavel Horák, CSc.

III. interní klinika – nefrologická, revmatologická, endokrinologická, FN a LF UP, Olomouc

- 1 Riggs, B. L. – Melton, L. J.: The worldwide problem of osteoporosis, insights afforded by epidemiology. *Bone*, 1995, 17, s. 505–511.
- 2 Cauley, J. A. – Thompson, D. E. – Ensurd, K. S., et al.: Risk of mortality following clinical fractures. *Osteoporosis Int*, 2000, 11, s. 556–561.
- 3 Kanis, J. A. – Johnell, O. – Oden, A., et al.: Ten years risk of osteoporotic fracture and the effect of risk factors on screening strategies. *Bone*, 2002, 30, s. 251–258.
- 4 Kanis, J. A. – McCloskey, E. V. – Johansson, H., et al.: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporosis Int*, 2013, 24, s. 23–57.
- 5 Lewiecki, E. M.: RANK ligand inhibition with denosumab for the management of osteoporosis. *Exper Opin Biol Ther*, 2006, 6, s. 1041–1050.
- 6 McClung, M. R. – Lewiecki, E. M. – Cohen, S. B., et al.: Denosumab in postmenopausal women with low bone mineral density. *N Engl J Med*, 2006, 354, s. 821–831.
- 7 Boyle, W. J. – Simonet, W. S. – Lacey, D. L., et al.: Osteoclast differentiation and activation. *Nature*, 2003, 423, s. 337–342.
- 8 Brown, J. P. – Prince, R. L. – Deal, C., et al.: Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. *J Bone Miner Res*, 2009, 24, s. 153–161.
- 9 Kendler, D. I. – Roux, C. – Benhamou, C. L., et al.: Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. *J Bone Miner Res*, 2010, 25, s. 72–81.
- 10 Cummings, S. R. – San Martin, J. – McClung, M. R., et al.: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med*, 2009, 361, s. 756–765.
- 11 Papapoulos, S. – Lippuner, K. – Roux, C., et al.: The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. *Osteoporosis Int*, 2015, 26, s. 2773–2783.
- 12 Bone, H. G. – Brandi, M. L. – Brown, J. P., et al.: Ten years of Denosumab (DMAB) treatment in postmenopausal women with osteoporosis. Results from the FREEDOM Extension trial. *Osteoporosis Int*, 2016, 27, dopl. 1, s. 135–136.
- 13 Hadji, P. – Kyvernitakis, I. – Kann, P. H., et al.: GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. *Osteoporosis Int*, publikováno online v dubnu 2016, DOI 10.1007/s00198-016-3623-6.
- 14 Boonen, S. – Ferrari, S. – Miller, P. D., et al.: Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. *JBMR*, 2012, 27, s. 963–974.
- 15 Miller, P. D. – Bolognese, M. A. – Lewiecki, E. M., et al.: Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. *Bone*, 2008, 43, s. 222–229.
- 16 Bone, H. G. – Bolognese, M. A. – Yuen, C. K., et al.: Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. *J Clin Endocrinol Metab*, 2011, 96, s. 972–980.
- 17 Aubry-Rozier, B. – Gonzalez-Rodriguez, E. – Stoll, D., et al.: Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. *Osteoporosis Int*, 2016, 27, s. 1923–1925.
- 18 Popp, A. W. – Zysset, P. K. – Lippuner, K., et al.: Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics. *Osteoporosis Int*, 2016, 27, s. 1917–1921.
- 19 Anastasilakis, A. D. – Makras, P.: Multiple clinical vertebral fractures following denosumab discontinuation. *Osteoporosis Int*, 2016, 27, s. 1929–1930.
- 20 McClung, M. R.: Cancel the denosumab holiday. *Osteoporosis Int*, 2016, 27, s. 1677–1682.